Refresh

GLENMARK PHARMACEUTICALS LTD. - Announcement under Regulation 30 (LODR)-Press Release / Media Release


Download
08 Jun 2021
Glenmark's interim data from PMS Study on Favipiravir (FabiFlu??) supports its safety and effectiveness in real world settings with no new safety signals or concerns in Covid-19<BR> patients

Source: BSE India

View all announcements for GLENMARK PHARMACEUTICALS LTD.
Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com